Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features

• Published in: PloS one 2013-02, Vol.8 (2), p.e56130-e56130
• Main Authors: Cheng, Chao-Wen, Su, Jen-Liang, Lin, Chiao-Wen, Su, Chun-Wen, Shih, Chun-Han, Yang, Shun-Fa, Chien, Ming-Hsien
• Format: Article
• Language: English
• Subjects: Adult; Aged; Alcohol; Alcohol use; B cells; Binding sites; Biology; Cancer genetics; Carcinoma, Hepatocellular - genetics; Carcinoma, Hepatocellular - pathology; Case-Control Studies; Clinical medicine; Confidence intervals; Disease susceptibility; Female; Gene polymorphism; Genes; Genetic aspects; Genetic polymorphisms; Genotype; Haplotypes; Hepatitis; Hepatocellular carcinoma; Hepatology; Humans; I-kappa B Proteins - genetics; Inflammation; Kinases; Liver - metabolism; Liver - pathology; Liver cancer; Liver cirrhosis; Liver Neoplasms - genetics; Liver Neoplasms - pathology; Male; Medical imaging; Medicine; Metastasis; Middle Aged; NF-kappa B p50 Subunit - genetics; NF-KappaB Inhibitor alpha; Oral cancer; Patients; Polymerase chain reaction; Polymorphism; Polymorphism, Genetic; Promoter Regions, Genetic; Proteins; Sarcoidosis; Statistical analysis; Studies; Transcription factors; Tumor necrosis factor-TNF; Tumors; Viruses
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0056130

Constitutive activation of nuclear factor (NF)-κB is frequently observed in hepatocellular carcinoma (HCC). The current study examined associations of polymorphisms within promoter regions of NFKB1 encoding NF-κB1 and NFKBIA encoding IκBα with the susceptibility of developing HCC and clinicopathological characteristics of the tumors. Genetic polymorphisms of NFKB1 and NFKBIA were analyzed by a real-time polymerase chain reaction (PCR) in 135 HCC patients and 520 healthy controls. The genotypic frequency of the NFKB1 -94 Ins polymorphism in HCC patients was significantly higher than that of the controls (adjusted odds ratio (AOR) = 2.23; 95% confidence interval (CI) 1.32∼3.77). No statistical significance was observed for the distribution frequency of the NFKBIA --519 C/T, -826 C/T, or -881 A/G genotype and haplotype polymorphisms between HCC patients and controls. Furthermore, female HCC patients carrying the NFKB1 -94 Ins polymorphism were associated with lower clinical stages and smaller tumor sizes. Our results indicate that the NFKB1 -94 Ins promoter polymorphism increased the risk of HCC, and may be applied as a predictive factor for the clinical stage and tumor size in female HCC patients.